# Mecuris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mecuris

- Industry: Medical Devices & Equipment
- Headquarters: Munich, Germany
- Website: www.mecuris.com
- Total disclosed funding: $4.1M
- Latest round: Series A (Jan 16, 2019)
- Investors on record: 5

## About

Mecuris GmbH specializes in developing advanced digital solutions for personalized prosthetics, utilizing innovative technologies to improve the quality of life for individuals with limb loss.Founded in 2016 in Munich, Germany, Mecuris GmbH focuses on delivering digital solutions for personalized prosthetic devices. The company, co-founded by Jannis Breuninger, Manuel Opitz, Simon Weidert, and Wolf-Peter Werner, is led by CEO Peter Fröhlingsdorf. Mecuris has successfully raised EUR 3.6 million in its Growth funding round on November 12, 2019, from investors such as Cluster Capital Partners, High-Tech Gründerfonds, Mulcan International Investments, Sana Kliniken AG, and Vesalius Biocapital. The total amount raised to date stands at EUR 3.6 million, with a current company valuation of EUR 28.567 mn.Mecuris GmbH provides a range of digital solutions tailored for personalized prosthetics. Their offerings focus on streamlining the design and manufacturing process for prosthetic devices, ensuring that users receive customized products that meet their unique needs. The company caters to healthcare providers and patients, enabling efficient and user-friendly solutions that enhance the integration of technology in prosthetic care. Mecuris operates globally, with strong market presence in Europe and plans for further expansion.The revenue of Mecuris GmbH is primarily generated through direct sales of their digital prosthetic solutions and associated services. The company employs a pricing model that accommodates various client needs, including health institutions and rehabilitation centers, ensuring accessibility to their innovations. Their flagship solutions are positioned to create value for both healthcare practitioners and prosthetic users, facilitating seamless integration into patient care plans.Mecuris GmbH aims to leverage its recent EUR 3.6 million funding from November 2019 to enhance product development and market reach. The company plans to introduce new digital tools for prosthetics in 2020, focusing on expanding into North American and Asian markets by 2021. The funding will be allocated towards enhancing technology infrastructure and strengthening partnerships with healthcare providers to drive growth and accessibility of their innovative solutions.

## Funding rounds

- Series A, Jan 16, 2019, $4.1M — Vesalius Biocapital, High-Tech Gruenderfonds, Bayern Kapital, Sana Kliniken AG, Mulcan International Investments
- Seed, Nov 21, 2016 — High-Tech Gruenderfonds, Bayern Kapital

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Seed, Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A
- Sana Kliniken AG — Series A
- Mulcan International Investments — Series A